Benjamin Walbaum, Medical Oncologist at Pontifical Catholic University of Chile, shared a post on LinkedIn:
“Happy to share our recently published paper in BMC Cancer:
Clinical and Biomarker Predictors of Early and Late Recurrence in Hormone Receptor-Positive Breast Cancer.
In this real-world cohort of 4,367 patients with HR+/HER2- early breast cancer, we evaluated clinicopathologic factors associated with early (<5 years) and late (5–10 years) recurrence.
Some key findings:
- 5- and 10-year invasive DFS were 85% and 70%, respectively
- Stage at diagnosis was the strongest predictor of both early and late recurrence
- Early recurrence was associated with higher tumor burden and proliferative features, including nodal involvement, grade 3, and higher Ki-67
- Late recurrence more often occurred in tumors with apparently lower-risk features, yet stage remained the main determinant of long-term risk
- Most recurrences were distant metastases, underscoring the need for sustained risk assessment over time
Our findings reinforce that in HR+ breast cancer, recurrence risk remains dynamic and prolonged. Readily available clinical and pathological variables still provide meaningful prognostic information and may help guide long-term treatment and follow-up strategies, especially where access to genomic tools is limited.
Congratulations to all co-authors and collaborators who contributed to this work.”
Title: Clinical and biomarker predictors of early and late recurrence in hormone receptor-positive breast cancer
Authors: Benjamín Walbaum, Francisco Acevedo, Elia Segui, Olga Martínez-Saez, María J. Vidal, Mauricio Camus, Tomas Merino, Lidia Medina, Karol Ramírez-Parada, Geraldine Murature, Manuel Manzor, Raúl Martínez, Fernando Araya, Constanza Pinto, Marisel Navarro, José Peña Duran, Carolina Ibáñez, Mauricio P. Pinto, César Sánchez
Read The Full Article
Other articles about Breast Cancer on OncoDaily.